Vaccinations in prisons: A shot in the arm for community health by Sequera, Víctor Guillermo et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=khvi20
Download by: [UNIVERSITAT DE BARCELONA] Date: 28 January 2016, At: 05:42
Human Vaccines & Immunotherapeutics
ISSN: 2164-5515 (Print) 2164-554X (Online) Journal homepage: http://www.tandfonline.com/loi/khvi20
Vaccinations in prisons: A shot in the arm for
community health
Víctor-Guillermo Sequera, Salomé Valencia, Alberto L García-Basteiro,
Andrés Marco & José M Bayas
To cite this article: Víctor-Guillermo Sequera, Salomé Valencia, Alberto L García-Basteiro,
Andrés Marco & José M Bayas (2015) Vaccinations in prisons: A shot in the arm for
community health, Human Vaccines & Immunotherapeutics, 11:11, 2615-2626, DOI:
10.1080/21645515.2015.1051269
To link to this article:  http://dx.doi.org/10.1080/21645515.2015.1051269
© 2015 The Author(s). Published with
license by Taylor & Francis Group, LLC©
Víctor-Guillermo Sequera, Salomé Valencia,
Alberto L García-Basteiro, Andrés Marco,
and José M BayasAccepted author version posted online: 09
Jul 2015.
Published online: 09 Jul 2015.
Submit your article to this journal 
Article views: 426
View related articles 
View Crossmark data
Vaccinations in prisons: A shot in the arm
for community health
Víctor-Guillermo Sequera1, Salome Valencia1, Alberto L García-Basteiro2,3,*, Andres Marco4, and Jose M Bayas1,2
1Preventive Medicine and Epidemiology Service; Hospital Clínic of Barcelona; Barcelona, Spain; 2ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB); Hospital Clínic - Universitat de
Barcelona; Rossello, Barcelona, Spain; 3Centro de Investigac¸~ao em Saude de Manhic¸a (CISM); Maputo, Mozambique; 4Health Services of Barcelona Men’s Penitentiary Center;
Barcelona, Spain
Keywords: communicable diseases, disease prevention, health promotion, prisons, vaccination
Abbreviations: HIPP, Health in Prisons Program; WHO, World Health Organization; IDU, injecting drug users; LGBT, lesbian,
gay, bisexual and transgender; HIV, human immunodeficiency virus; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis
C virus; HTLV, human T-lymphotropic virus; MSM, men who have sex with men
From the ﬁrst day of imprisonment, prisoners are exposed
to and expose other prisoners to various communicable
diseases, many of which are vaccine-preventable. The risk of
acquiring these diseases during the prison sentence exceeds
that of the general population. This excess risk may be
explained by various causes; some due to the structural and
logistical problems of prisons and others to habitual or
acquired behaviors during imprisonment. Prison is, for many
inmates, an opportunity to access health care, and is
therefore an ideal opportunity to update adult vaccination
schedules. The traditional idea that prisons are intended to
ensure public safety should be complemented by the
contribution they can make in improving community health,
providing a more comprehensive vision of safety that
includes public health.
Introduction
In any prison there is usually a conflict between the objectives
of safety and security, control of the prison population and pub-
lic health goals. Since 1995, the Health in Prisons Program
(HIPP) of the World Health Organization (WHO) has
attempted to lead and guide this broad discussion between prison
safety and global health, using a perspective derived from the
experiences and recommendations applied in the European
region. This review aims to broaden and deepen this debate,
proposing and arguing why vaccination strategies should be the
spearhead of the health system within the prison system.
Prisons and Health,1 a recent HIPP publication, suggests vari-
ous aspects that should be considered to improve the physical
and mental health of prisoners and reduce the risks of imprison-
ment for health and the society using a comprehensive human-
rights based approach. This approach, like others, presents some
inconsistencies and may not be effective in the daily health care
provided to prisoners, especially with respect to the control of
vaccine-preventable diseases and recommendations on vaccina-
tion schedules.2
After water purification, vaccination is probably the interven-
tion that has most helped to improve human life expectancy.3
Vaccination is a very efficacious and cost-effective intervention,
as it may eliminate and even eradicate some infectious diseases.
For these reasons, of all the potential health interventions in pris-
ons, those related to vaccine-preventable diseases should be a
priority. Access of prisoners to vaccination has a direct impact
not only on the target population, but also the wider community.
In general, vaccine administration criteria are based on age
(routine vaccination schedule) and specific risk, either individual
or group (e.g., specific vaccines for people with chronic illness,
vaccines for health workers). The high coverages achieved by rou-
tine vaccination result in herd immunity, which can reduce or
even halt the transmission of some contagious diseases. Some spe-
cific vaccination strategies go further, requiring an active search
for individuals or groups that are difficult to access and represent
pockets of people at high risk for vaccine-preventable diseases or
their complications. These directed interventions can signifi-
cantly improve vaccination coverages compared with traditional
vaccination strategies. Prisons, with a population detained in a
confined space, provide a paradigmatic opportunity for vaccina-
tion interventions.4
In addition to an accessible population, prisons present an
opportunity to achieve enormous benefits using a good vaccina-
tion program, mainly because this population is at higher risk of
contracting diseases than the rest of the population.2 The many
determinants of this increased risk of acquiring infectious diseases
in prisons (with a corresponding impact on the community)
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include overpopulation and overcrowding, high levels of social
vulnerability and prison lifestyles, the prevalence of communica-
ble diseases and the rotational dynamics of the prison population.
There are surprisingly few thorough reports on this topic
globally, and operational research on vaccination programs and
coverages in prisons is limited.5 A possible explanation is that
prisons were designed and structured solely to ensure public
safety. This, possibly limited, idea of safety, which persists today,
works against the concept that prisons could offer real opportuni-
ties to access health care and play an important role in a global,
integrated strategy for reducing the incidence of vaccine-prevent-
able diseases, both inside and outside prisons. This perspective
positively extends the concept of safety.
Importance of vaccination in prisons
From the perspective of vaccinology, prisons should be con-
sidered a public health priority for 4 main reasons (Table 1):
Access to vulnerable social groups
The prison population is mainly composed of young men
from the most disadvantaged social classes and educational levels.
Marginal populations are often overrepresented in prison popula-
tions.6 Most prisoners make little use of national health services
when at liberty.6-8 Today’s global mobility has increased the
number of foreign prisoners. Immigrants, depending on their
origin, may have different health needs from the autochthonous
population, including the need for vaccination. In Spain, for
example, the foreign population is 9.7% of the total, but it never-
theless represents about a third of the prison population.9 Other
minorities in prison, such as lesbian, gay, bisexual and transgen-
der (LGBT) persons are particularly vulnerable groups.1 Most
female prisoners are of childbearing age and 3–5% are in the
gestation period, and therefore require specific care.10,11
As in the general population, the proportion of prisoners aged
65 y is progressively increasing and, in some cases, the increase
is even higher inside than outside prison.12 The aging process is
accelerated in prison, i.e., chronic diseases and disabilities
develop between 10–15 y earlier than in the rest of the popula-
tion.1,13 As a result, some criminal justice systems consider the
equivalent to the medical cutoff of 65 y to be 55 or even 50 y in
prisoners,14,15 with the corresponding implications for vaccina-
tion policies, such as influenza vaccination.
Reports on injecting drug users (IDU) before prison admis-
sion show a high use (5% to 38%) compared with the general
population.16 Proportionally, 3 times as many prisoners smoke
compared with the general population,17 and prisoners have a
higher rate of alcohol abuse.18 A study from the US showed that
prisoners had a higher prevalence of hypertension, diabetes, myo-
cardial infarction and asthma than age- and sex-matched people
outside prison.19,20 The prevalence of female prisoners with
abnormal cervical cytology is much higher than in the general
population.11,21 Deaths from lung cancer, non-Hodgkin lym-
phoma and liver cancer are more common in inmates compared
to the general population.22,23
Unsurprisingly, rates of tuberculosis in prisons may exceed
rates in the community by 5 to 70 times.2,24,25 US studies sug-
gest that 25% of HIV-infected individuals26,27 and 40% of
chronic carriers of viral hepatitis have been incarcerated.27 Stud-
ies show the prevalence of hepatitis C virus (HCV) infection in
prisoners is more than 10 times higher than that of the general
population.28-33 The prevalence of hepatitis B virus (HBV) infec-
tion is between 1.8 and 62%, and is higher than that of the gen-
eral reference population in all studies (Fig. 1).30,31,34-42
These clinical and social factors describe a population that
could benefit from various vaccination strategies: prisoners whose
lifestyle before imprisonment makes them more susceptible to
acquiring vaccine-preventable diseases with potentially severe
complications and even death.
Prisoners are at high risk of vaccine-preventable diseases during
imprisonment
It is estimated that approximately 30% of prisoners are
sexually active in prison, and most will not use methods that
minimize the risk of the sexual transmission of diseases.43,44
Surveys in Welsh prisons show 14% of prisoners were men
who have sex with men (MSM) and, of these, 20% had sex
with men only during their period of incarceration.45 In
addition, a considerable proportion of sex in prison is non-
consensual and, therefore, violent. US studies have shown a
rate of rape of 3–5% in male prisoners.46 The true figures
are probably higher, and in some groups, such as LGBT, the
rates are up to 10 times greater.1,47 It is also estimated that
the prevalence of physical violence, not necessarily sexual, is
much greater in prisoners.1,48
Tattooing and piercing are prevalent in prisons and are closely
linked to prison sub-cultures: 53% of UK prisoners have a tattoo,
of which the tattooing occurred in prison in 11%. Due to the
Table 1. Importance of vaccination in prisons
Access to vulnerable social groups
Groups with little normal access to the health system
Prisoners come from disadvantaged social strata (educational and
socioeconomic level)
Greater history of illicit drug use before entering prison
Greater history of alcohol abuse
High prevalence of carriers of communicable diseases and other morbidities
Overrepresentation of especially-vulnerable groups: LGTB, sex workers,
immigrants
Progressively greater proportion of elderly adults
High risk of acquiring infections in prison
Sexual activity, often unprotected, in prisons
High rate of starting or returning to illicit drug use (injectable and non-
injectable)
Tattoos / piercings
Physical violence (injuries, rapes)
Permanent contact with the community
High rotation rates in prison (short sentences, transfers)
Visits/ staff/ temporary release
High risk of extreme behavior in the ﬁrst weeks after release (drug abuse)
Prison population is known and concentrated in one place
Population identiﬁed and easily located
LGBT: gay, lesbian, transgender, bisexual.
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scarcity of sterile equipment,
inadequate instruments, with an
increased risk of disease transmis-
sion (guitar strings, clips, nails),
are often used.49-51 According to
studies analyzing self-reported
attitudes, the prevalence of illicit
drug use in prisons varies between
22 and 48% worldwide, and
IDU is between 6 and 26%, with
25% of IDU being initiated in
prison.40,52-54
The structural and logistical
instability of many prisons world-
wide, an increasingly precaution-
ary penal system with progressive
overpopulation and overcrowd-
ing, poor ventilation in cells, the
lack of sanitation and hygiene,
poor food quality, limited avail-
ability of health care, etc.,55 are
additional risk factors for greater
transmission of vaccine-prevent-
able diseases. In addition, these
conditions often violate funda-
mental human rights.1
Of the high incidence of new
cases of vaccine-preventable dis-
eases in prison, a significant frac-
tion should be considered attributable to the persistence of
endemic diseases or the development of epidemics in the com-
munity.24 (Fig. 2).
Prisoners are in constant contact with the rest of the community
Although prisons are closed institutions, inmates are in fre-
quent contact with the community. Prison staff, visitation rights,
day leave and other “privileges” allow inmates access to the rest
of the community, with which it interacts. In addition, many
sentences are relatively short and almost all the prison population
will, at some point, be reintegrated into society. The annual flow
or rotation of prisoners can be 5 times higher than the total per-
manent prison population,56,57 which is an indirect indicator of
the close interaction between prisoners and the rest of society.
Moreover, the highest frequency of risk behaviors such as drug
abuse are reported in the first 3–4 weeks after release.58
Prisoners are accessible and susceptible to vaccination
Theoretically, prisoners’ access to vaccination should be sim-
ple. Prisoners are an identified, recorded, defined and easily-
accessible population and this should ensure high vaccination
coverages with satisfactory health outcomes in prisons.4,59
Biological risks in prison and recommended vaccines
Despite regional epidemiological characteristics (e.g., higher
seroprevalence of HTLV I/II or Trypanosoma cruzi in Brazilian
prisons,60 and a higher prevalence of intestinal parasites in
Ethiopian prisoners61) most of the biological risks to which pris-
oners and prison staff are exposed are quite similar throughout
the world (Table 2). In the following paragraphs, we describe
evidence on vaccination and current recommendations for pris-
ons, accompanied by an epidemiological overview of disease
inside and outside prison (Tables 3 and 4).
Hepatitis B
Currently, 240 million people worldwide suffer from
chronic hepatitis B,62 which caused 786,000 deaths world-
wide in 2010. The prevalences documented in prisons are
always higher than in the general reference population,19,63
with IDUs having the highest risk. Data on the prevalence of
HBsAg vary by region (Table 3).31,34,35,42,64-71 Whether due
to the progressive introduction of routine vaccination of
younger cohorts or to the longer exposure time, the disease
prevalence is usually greater in older adults.40
Although HBV vaccination has been recommended since 1982
in prisons, the proportion of susceptible individuals is still higher
than is acceptable and, in countries like France and the US, bar-
riers to the correct implementation of recommendations have only
been overcome in the last decade.72,73 In middle-and low-income
countries, HBV vaccination is far from routine. It has been shown
that, for every dollar invested in HBV vaccination, $2.13 is saved
in later treatment and care costs.74 Current recommendations
may vary and should be adapted to the capabilities of the prison;
ideally, all new prisoners who are not immune or whose serology
Figure 1. Comparison of US estimates of lifetime prevalence (%) of viral hepatitis risk factors and seropreva-
lence of hepatitis A, B and C virus exposure in inmates vs. the overall population 2009. HBc IgG, IgG antibody
to hepatitis B core antigen; HCV Ab, antibody to hepatitis C Total virus. HAV IgG, IgG antibody to hepatitis A.
MSM, men who have sex with men. Figure modiﬁed from “Viral hepatitis in incarcerated adults: a medical
and public health concern;” by Hunt, DR & Saab S.44
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is unknown should be vaccinated.1,75 HBV serology testing is rec-
ommended since the identification of chronic carriers is another
determining factor in controlling the disease. If all prisoners can-
not be vaccinated, priority should be given to those with known
risk factors, such as IDUs, prisoners with chronic diseases, and
risk populations such as immigrants or indigenous people, among
others. The rapid (0, 1 and 2 m) and extra-rapid (0, 7 and
21 days) schedules facilitate adherence and compliance, and have
been shown to provide optimal seroprotection.76,77
Hepatitis A
According to global estimates, there were 126 million acute
cases of hepatitis A, and 35,245 deaths in 2005.78,79 Few out-
breaks have been described in prisons, although outbreaks are
increasing in IDUs and MSM.52,80-85 In Italy, Rapicetta et al81
observed a prevalence of HAV antibodies in 86.4% of prisoners,
which was higher in foreign prisoners (92.1%), of whom none
reported being vaccinated. In the
US, the reported prevalence of
past HAV infection was 22% to
39%, comparable to the general
population.86,87 The prevalence
of HAV antibodies in Luxemburg
was 57.1% and 65.9% in IDUs
versus non-IDUs, respectively.85
HAV vaccination is recom-
mended for all new prisoners with
an unknown immune status and
those who are unvaccinated.1,2
Previous serology testing is less
important because HAV infection
is a self-limiting disease without
chronic carriers. If all susceptible
prisoners cannot be vaccinated,
they should be prioritized accord-
ing to age, origin and risk factors
(IDUs, MSM and hepatic risk fac-
tors).87,88 For HAV vaccination
alone, the recommended schedule
is 0 and 6 months, although the
accelerated (0, 1, 2 m) and rap-
idly-accelerated (0, 7, 21 and
1 year) HAV/HBV schedules
have also been used.89,90 If accel-
erated schedules are used, it is
important to administrate as
many doses as possible, as one
dose of HAV vaccine (> 90% of
immunogenicity) alone gives
more protection than one dose of
the combined HAV/HAB vac-
cine. The administration of com-
bined schedules is also more
complex.86,91
Tetanus/diphtheria/pertussis
Globally, the 1989 WHO neonatal tetanus elimination pro-
gram resulted in a reduction in new cases of 92% by 2008.92 A
total of 4,680 (2013) cases and 2,500 deaths due to C. diphtheria
were reported in 2011.93 A total of 136,000 cases of pertussis
were reported in 2013, and 89,000 deaths were reported in
2008.94 There is little data on the coverage of the combined vac-
cine in prisons. A seroprevalence study in a Canadian prison
found 49% of inmates were incompletely vaccinated.95
The recommendations are similar to those for the general
population: people in whom prior vaccination cannot be proven
should be vaccinated at 0, 1 and 6–12 months, and people not
vaccinated for 10 y should receive a booster dose.75,96
Pneumococcal disease
In 2005, 1.6 million people died from pneumococcal
disease.97 The prevalence in prisons is unknown and few out-
breaks have been reported.98,99 Despite this lack of data, the high
Figure 2. Transmission of communicable diseases inside and beyond prisons. Figure modiﬁed from
Guidelines for the Control of Tuberculosis in Prisons, WHO 1998.153
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burden of non-communicable diseases ¡ of which chronic lung
disease is one of the most frequent ¡ is an important risk factor
for invasive pneumococcal disease (IPD).1,100 The risk of IDP in
some prisoners, such as those infected with HIV or splenectom-
ized is about 100 times higher than in healthy prisoners, and
therefore pneumococcal vaccination should be routine in pris-
ons.101 The current recommendation is that prisoners aged 
65 y and those with risk factors should be vaccinated.1,75 The
recent availability of the 13-valent pneumococcal conjugate
vaccine (PCV13) in adults is an option that provides more-effi-
cient protection.102,103
Seasonal influenza
Global estimates suggest annual seasonal influenza epidemics
result in approximately 3 to 5 million cases of severe illness and
250,000 to 500,000 deaths. Many seasonal influenza outbreaks
have been reported in prisons.104-109 James et al.110 studied
influenza outbreaks in 43 closed institutions (8 prisons) in the
last 120 y in the UK, and found an attack rate of 3% to 69%.
Seasonal influenza vaccination in prisons has long been rejected,
although it has often been used for secondary prevention in the
event of outbreaks.111,112 The influenza A (H1N1) pandemic in
2009 may have acted as an important stimulus for organizations
like the CDC and the UK Health Protection Agency to introduce
vaccination for primary prevention in prisons, as coverages in US
prisons were <50% in 2009.113
All prisoners and staff should receive the seasonal influenza
vaccine before the virus becomes active in the community,
instead of just vaccinating people aged >65 y.1,2
Mumps, measles and rubella
The disease burden of these 3 diseases is higher in children,
although it is more severe in adults.114 Larney et al. studied the
susceptibility of new prisoners in 7 Australian prisons; 41% were
susceptible to mumps, 16% to rubella, 13% to measles and 10%
to varicella, similar to the general population.37 In Switzerland,
susceptibility to mumps was low (6%) in immigrant prisoners.115
In a Canadian correctional facility, 2% of young people were sus-
ceptible to one of the 3 viruses.95
Outbreaks have been described in prisons,116,117 but have
declined significantly since the introduction of routine vaccination.
Table 2. Biological Hazards Prison
Transmisson by serum
HIV
Hepatitis B*
Hepatitis C
Respiratory transmission
Tuberculosis*
Inﬂuenza*
Measles*
Mumps*
Rubella*
Meningococcal infection*
Pneumococcal infection*
Enteric transmission
Hepatitis A*
Transmission by contact
Herpes simplex
Varicela Zoster*
Scabies
Viral conjuntivitis
HPV*
Diphtheria*
Tetanus*
*Vaccine available.
Table 3. Prevalence of Hepatitis B in prison
Country (reference) City, State or Region Survey year Prisons Population Seroprevalence (%)
Australia (35) New South Wales,
Queensland, Tasmania
and Western Australia
2004, 2007, 2010 29 1388 914(IDUs) 2.3% 3.1%(IDUs)
Brazil (68) Goias (State) 2007–08 1 150 0.7% – 1.3%
Brazil (69) Sao Pablo (State) 2003 1 333 2.4% – 1.2%
Croatia (65) All country 2005–2007 20 3290 1.3%
England and Wales (66) Different regions 1997 – 98 8 3930 775 (IDUs) 8% 20%(IDUs)
Ghana (70) Different regions 2004–05 8 1366 25.5%
Hungary (41) All country 2007–09 20 4894 1.5%
Iran (64) Isfahan 2009 2 970 (IDUs) 3,3% (IDUs) 13,9% (IDUs)
Mexico (67) West central Mexico 2007 1 30 20%
Nigeria (71) Nasarawa (State) 2007 4 300 23%
Pakistan (34) Karachi 2007–08 1 357 5.9%
Spain (31) All country 2008 18 342 2.6%
USA (42) Different States Studies between
1975 and 2005
25 nd / meta-analysis
23 studies
0,9% – 8% 6,5% – 42%
EEUU: United States of America. IDUs: prevalence among injecting drug users. HbsAgDhepatitis B surface antigen; HBc IgGDIgG antibody to hepatitis B core
antigen.
* D hepatitis B surface antigen (HbsAg).
** D IgG antibody to hepatitis B core antigen (HBc IgG).
*** D HbsAg plus HBc IgG positives. nd D no data.
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Susceptibility studies in prisoners provide similar results to those
of the general population, and there is limited knowledge of the
history of vaccination in prisoners who have suffered these dis-
eases. These records are critical because true herd immunity
requires high coverages (95% for mumps).118 The ideal recom-
mendation would be to vaccinate all new prisoners who are sus-
ceptible or whose immune status is unknown.1,75 If selective
vaccination is the option chosen, women of childbearing age, the
country of origin and age according to the dates of routine intro-
duction of the vaccine in different countries could serve to select
priorities. The regimen is 2 doses at 0 and 1 months. If childhood
vaccination without information on the current immune status is
reported, one dose of vaccine should be administered.75
Human papillomavirus
Globally, in 2010, the estimated prevalence of human papil-
lomavirus (HPV) infection in women with normal cytological
findings, was 11.7%, with a peak in women aged < 25 y
(21.7%).119 The prevalence of HPV in males is less homoge-
nous, varying from 49.4% (HIV-) and 78.2% (HIV C 78.2%)
in sub-Saharan Africa120 to 1% to 84% in the EU and 2% to
93% in the US in groups at low and high risk of HPV, respec-
tively.121,122 A study of 190 female prisoners in the Amazon
region of Brazil found a prevalence of 10.5%.123 In Taiwan, the
prevalence in 150 female prisoners was 55.4% (47.4% in HIV-
and 63.9% in HIV C ).124 In Mexico, the prevalence was
20.7% in 82 prisoners.125 In Spain, a prevalence of HPV of
between 27.4% and 46% of female prisoners was
recorded.126,127 These prevalences are higher than in the general
population of the respective countries.
Since its approval, the HPV vaccine has been used in some
juvenile detention centers in the UK and USA.128,129 Henderson
et al.128 described its use in US prisons, and found that lack of
knowledge about the vaccine and the short period in prison were
the main barriers to successful vaccination. New female prisoners
are at high risk for HPV and cervical cancer,130 and vaccination
should be initiated or completed, although the recommended
upper age limits for vaccination vary between countries. Prioriti-
zation of immunocompromised subjects may be appropriate. For
male prisoners, vaccination is not a priority,122 but MSM and
immunocompromised subjects should receive special atten-
tion.131 The normal schedule of 0, 1–2 and 6 months is
recommended.
Meningococcal meningitis
There is no reliable estimate of the global disease burden. The
greatest age-adjusted incidence rate is found in the African men-
ingitis belt.132 Of the 12 serogroups identified, 6 can cause out-
breaks (A, B, C, W, X and Y), and these have a very-specific
geographical distribution. Some outbreaks have been reported in
prisons.133-135 In the UK, one dose of meningococcal C conju-
gate vaccine is administered to prisoners aged <25 years,75 iden-
tical to the policy in the general population.
Varicella
The global disease burden is about 4.2 million severe compli-
cations and 4,200 deaths annually.136 There is a high risk of
transmission and outbreaks in prisons,2,75 even when the percent-
age of susceptible inmates is low. In an outbreak in a California
prison, 2% of exposed prisoners were susceptible.137 In Switzer-
land, 12.7% of prisoners were susceptible, with immigrants hav-
ing a risk nearly 6-fold greater than the general population.138 In
an Italian prison, the susceptibility was 14.5%.139 In a global
seroprevalence study in an Australian prison, 10% of prisoners
were susceptible.37
There are few recommendations on the use of the varicella
vaccine in prisons: some indicate serological screening and vacci-
nation of all non-immune prisoners, in order to reduce the
potential risk of outbreaks.2,140 General vaccination is also rec-
ommended for new prisoners if an outbreak is suspected.141
Tuberculosis
The overall prevalence of tuberculosis (TB) in 2013 was 159
cases per 100,000 population, with an incidence of 126/100,000
and a mortality of 16/100,000.142 More than one million inci-
dent cases had HIV. In some countries, the incidence in prisons
is up to 100-fold that of the general population.143 A systematic
review by Baussano et al.24 estimated a mean annual incidence in
prisons of 237.6 (interquartile range (IQR): 156–639) cases per
100,000 people and 1,942 (IQR: 1,045–2,778) per 100,000 in
high and medium-low income countries, respectively. In a
WHO literature review, prisons from Russia (4,560 per
100,000) and Georgia (5,995 per 100,000) had the highest prev-
alence rates, followed by some African countries.144 The BCG
vaccine is currently only recommended in children born in coun-
tries with a high disease burden and medical personnel in close
contact with cases of TB, especially multi-resistant bacilli.145 The
vaccine is not indicated in specific prevention programs in pris-
ons due to its lack of efficacy in preventing TB in adults.1,146
Concluding remarks
The vast majority of epidemiological data on vaccine-prevent-
able diseases and the use of vaccines in prisons comes from stud-
ies in high-income countries, where prison health programs are
more developed and recommendations take into account the par-
ticularities of the respective population. Prison conditions in
medium-low income countries are generally worse, the risk for
vaccine-preventable diseases is much higher, and the scarcity of
resources makes the application of new vaccines, such as conju-
gate vaccines, which are usually more expensive, more difficult.
The prison population and the proportion of elderly persons
within it are increasing worldwide, pushing up global incarcera-
tion costs. The case of the US is the prototype of this problem;
the American penal system costs more than 74 billion dollars per
year, eclipsing the GDP of more than 130 countries.147 Address-
ing these high costs with a model of healthy prison initiatives
such as vaccination ¡ although this would involve further invest-
ment ¡ would generate indirect savings for the health system
and have a positive impact on overall welfare. However, there are
few available studies on the cost-effectiveness of vaccination in
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prisons and the performance of their health systems. No study
has evaluated the introduction of an integrated prison vaccina-
tion program. This is an important research gap that could
potentially aid decision making. Most studies focus on a single
vaccine, mainly hepatitis B vaccine.74,91,115 Jacobs et al.91 exam-
ined the cost effectiveness of substituting bivalent hepatitis A/B
for the hepatitis B vaccine in US prison inmates, and state rates
of hepatitis A. In states with high rates of hepatitis A (200% the
national average) introduction of hepatitis A/B vaccination
would prevent 466 hepatitis A infections, 60 hospitalizations, 1.6
premature deaths, and the loss of 28 life-years ($ 22,819 per life-
year saved). In states with lower rates (100–200 and <100%) the
cost-effectiveness would be $ < 0 and $ 2,131 per life-year saved,
respectively. This could help reduce morbidity and mortality,
therefore reducing costs. A study in a Swiss prison calculated the
reduction in costs due to measles vaccination in accordance with
origin and age. It was estimated that 35 % of inmates were sus-
ceptible to measles and required vaccination. This approach
achieved a reduction of 62% in vaccinations in 3,000 prisoners
yearly, resulting in annual cost savings of € 72, 000. The high
cost of potential outbreaks was an important issue also taken into
account.115 Likewise, there are few studies of the situation of
female, elderly or mentally-ill inmates. In the context of prisons,
it is imperative to agree on whether vaccination strategies should
lower the age cut-off for considering a patient as “older” from the
normal 65 y to 50 or 55 years, and to integrate current vaccina-
tion recommendations to this effect in the specific case of prison-
ers (Table 5).
The complexity of the prison context in countries or regions
makes it impossible to make general “one-size-fits-all” recom-
mendations. The first major step recommended is that the
prison system delegates the responsibility and authority for pris-
oner’s health care to the health system, because this is part of
public health.148,149 This would guarantee the right to primary
health care for every prisoner: in many cases this might be a first
contact with the health system. Providing healthcare access to
prisoners helps reduce inequalities outside prison and facilitates
reintegration. Vaccines should be the spearhead of a compre-
hensive approach based on primary care. First, updating of the
vaccination of healthy adults should be ensured (Table 6).
Secondly, access to other vaccines according to individual risk
should also be ensured. Thirdly, vaccines should be offered
according to agreed criteria based on local epidemiological data
and the availability of funds. Prison staff should receive the
same treatment. Thereafter, it is essential to evaluate the quality
of the strategies introduced. In the UK, one indicator of the
quality of care in prisons is that 80% of prisoners should be
vaccinated against hepatitis B during the first 3 months of
imprisonment.150 It is debatable whether offering vaccination
immediately upon imprisonment is the best strategy, since the
psychological burden felt by new inmates might not provide the
optimum frame of mind, could be an obstacle to compliance
with the recommended immunization schedule, and might lead
to rejection of the first dose or result in incomplete vaccination.
Prisoners may be less likely to reject vaccination if this is offered
within an integrated health care policy. Therefore, ideally, vacci-
nation of prisoners should not be automatic, but should be inte-
grated into an approach that shows respect for people and their
rights. Moreover, refusal to vaccinate may be due to misinfor-
mation, poor knowledge of the vaccine, and fear of needles or
adverse reactions. Peer educators can play a vital role in educat-
ing other prisoners about vaccine acceptance. Peers may be the
only people who can speak candidly to other prisoners about
ways to reduce the risk of contracting infections. Peer-led educa-
tion has been shown to be beneficial for peer educators them-
selves: individuals who participate as peer educators report
significant improvements in self-esteem.6 However, as with
other educational programs, preventive education between peers
is difficult when prisoners have no means to adopt the changes
that would lead to healthier choices. Peer support groups need
to be adequately funded and supported by staff and prison
authorities, and have the trust of their peers, which can be diffi-
cult when the prison system appoints prisoners as peer educators
because it trusts them, rather than because the prisoners trust
them. However, the main reported barrier to achieving com-
plete vaccination schedules remains the high turnover and
dynamics of prisoners.151,152 The full integration of the prison
health system should strengthen infection control in prisons and
Table 5. Research gaps: improving the introduction of prison vaccination
programs
1 Cost-effectiveness assessments of integrated vaccine
program introduction
2 Health technology assessment of prison vaccine
program introduction
Promotion of reports on prison vaccination with a focus
on developing countries
4 Promotion of studies on the implementation
of vaccination in female prisons
5 Gender studies on vaccination in prisons
6 Research on elderly prisoners and the impact of vaccines
in this group
7 Research on the impact of vaccines on mentally-ill inmates
Table 6. Recommended steps to ensure vaccination schedules in prisons
Integration of health
services with the
prison system
1 The authority and responsibility
for health care in prison
lies with the health system
2 Ensure the integration of
prisons with other community
health services
Application of a
vaccination schedule
3 Ensure compliance with the
vaccination schedule for
healthy adults
4 Ensure access to vaccination
of persons with speciﬁc risk
factors (HIV, HCV, MSM)
5 Establish vaccination priorities
for each prison according
to identiﬁed epidemiological
factors and local resources
6 Evaluate strategies
(coverage, adherence, follow
up outside prison)
2622 Volume 11 Issue 11Human Vaccines & Immunotherapeutics
D
ow
nl
oa
de
d 
by
 [U
NI
VE
RS
IT
AT
 D
E 
BA
RC
EL
ON
A]
 at
 05
:42
 28
 Ja
nu
ary
 20
16
 
facilitate monitoring of vaccinations and other treatments after
the prisoner is released.
Such policies would make it easier to prevent vaccine-prevent-
able diseases in prisoners, prison staff, families and the commu-
nity in general, and offer benefits to national health systems,153
as they would ensure that the prisoners would no longer be a
pocket with a high burden of communicable diseases. Therefore,
locally-agreed vaccination programs in prisons, based on reported
evidence, are essential. Prisoners may suffer the loss of liberty but
should not be punished by disease. Healthy prisons result in
healthier communities, and vaccines are an essential tool in
achieving this goal.
Article search criteria
We searched Medline/Pubmed for articles from the last
10 years, except for diseases where little data is available,
where no time limits were set. The search terms included the
MeSH terms (*correctional OR prison* OR jail*) and, for
each vaccine-preventable disease of interest (infection OR
infections/epidemiology OR infection OR infections/preven-
tion and control). The references of publications located were
scrutinized and relevant articles included. The gray literature,
guidelines and reports of public health agencies included
were identified through the Google advanced search engine.
English, Spanish and Portuguese language texts were
included. In the text, the term “prison” refers to all types of
institution authorized by a country in which detainees are
held.
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